Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3756 - A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)


09 Oct 2016


Poster display


Rosa Nadal


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


R. Nadal1, H.L. Parnes1, D.C. Francis1, L.M. Cordes1, M. Berninger1, R. Costello1, L. Folio1, M. Linderberg1, L. Machado1, S.M. Steinberg1, J.J. Wright1, Y.M. Ning1, D.P. Bottaro1, W.L. Dahut2, A.B. Apolo3

Author affiliations

  • 1 Medical Oncology, National Cancer Institute, 20892 - Bethesda/US
  • 2 Genitourinary Malignancies Branch, National Cancer Institute, 20892 - Bethesda/US
  • 3 National Institutes Of Health, Genitourinary Malignancies Branch, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US


Abstract 3756


Hepatocyte growth factor (HGF) and its receptor (MET) are activated in UC. In translational studies, cabozantinib, a receptor tyrosine kinase inhibitor primarily targeting MET and VEGFR2, reversed HGF-driven UC cell growth and invasion.


In this phase II study, pts received cabozantinib 60 mg/day in 28-day cycles in 3 cohorts: 1) mUC, 2) bone-only mUC, and 3) metastatic rare bladder histology. Primary objective was overall response rate (ORR) by RECIST v1.1. In cohort 1, we also report on the tumor responses by site of metastases (mets). Secondary objectives were to assess the progression-free survival (PFS) and overall survival (OS) in all cohorts.


Of 67 pts enrolled, 70% of male, median age: 63 (22–82), KPS 80% in 73% pts. Primary sites: 69% bladder, 25% upper tract, 6% both. No. prior therapies: 1/2/3/ ≥ 4 (range 1–6) in 34/39/16/9% of pts, respectively. Of 41 evaluable pts in cohort 1, there was 1 complete response (CR), 7 partial responses (PR) (ORR = 19.5%; 95% CI: 8.8–34.9%), 18 stable disease (SD), and 15 progressive disease (PD). Median progression-free survival (mPFS): 3.7 mos(95% CI: 2.3–6.5); 6-month PFS: 38.0%(95% CI: 23.3–52.6%). Median overall survival (mOS): 8.2 mos (95% CI: 5.2–10.3); 6-month OS: 65.1%(95% CI: 48.3–77.6%); 12-month OS: 25.7% (95% CI: 13.0–40.3%). ORR in cohort 1 was evaluated by site of mets in 63 target-lesions: 25.3%lung,/9.5%liver/6.3%adrenal/1.6%kidney/1.6% pancreatic/39.8% LN/15.9% ST. Lung mets had 25% PR/75% SD/0%PD. Treatment resulted in lung lesion cavitation, which could not be interpreted as CR (at best PR). Liver mets had 83.3%SD/16.7%PD. There was no ORR in liver/adrenal/kidney/pancreatic mets. LN mets had 8%CR/8%PR/72%SD/12%PD. ST mets had 90%SD/10%PD. Of 5 pts in cohort 2, 60% had improvement by NaF FDG/PET. mOS: 9.3 mos (95% CI: 3.6–12.5). Of 10 evaluable pts in cohort 3, there were 0%CR/PR/50%SD/50%PD. mPFS: 2.9 mos (95% CI: 1.8–3.7); mOS: 4.6 mos (95% CI: 2.6–8.0).


Cabozantinib has clinical activity in relapsed/refractory pts with mUC. Lung and LN mets had higher ORR. Lung lesion cavitation was frequently noted in responders. Further studies are underway to correlate responses with MET expression, immune subsets, CTCs, and cytokine/mutational profiles.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings